vs

Side-by-side financial comparison of Murphy USA Inc. (MUSA) and Vertex Pharmaceuticals (VRTX). Click either name above to swap in a different company.

Murphy USA Inc. is the larger business by last-quarter revenue ($4.7B vs $3.2B, roughly 1.5× Vertex Pharmaceuticals). Vertex Pharmaceuticals runs the higher net margin — 37.3% vs 3.0%, a 34.3% gap on every dollar of revenue. On growth, Vertex Pharmaceuticals posted the faster year-over-year revenue change (9.5% vs 0.7%). Vertex Pharmaceuticals produced more free cash flow last quarter ($348.6M vs $128.8M). Over the past eight quarters, Vertex Pharmaceuticals's revenue compounded faster (8.9% CAGR vs -1.0%).

Murphy USA is an American corporation based in El Dorado, Arkansas that operates a chain of retail gas stations that are primarily located in proximity to Walmart stores. It was founded as a spin-off of Murphy Oil in 2013.

Vertex Pharmaceuticals Incorporated is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry. It maintains headquarters in Boston, Massachusetts, and three research facilities, in San Diego, California, and Milton Park, Oxfordshire, England.

MUSA vs VRTX — Head-to-Head

Bigger by revenue
MUSA
MUSA
1.5× larger
MUSA
$4.7B
$3.2B
VRTX
Growing faster (revenue YoY)
VRTX
VRTX
+8.8% gap
VRTX
9.5%
0.7%
MUSA
Higher net margin
VRTX
VRTX
34.3% more per $
VRTX
37.3%
3.0%
MUSA
More free cash flow
VRTX
VRTX
$219.8M more FCF
VRTX
$348.6M
$128.8M
MUSA
Faster 2-yr revenue CAGR
VRTX
VRTX
Annualised
VRTX
8.9%
-1.0%
MUSA

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
MUSA
MUSA
VRTX
VRTX
Revenue
$4.7B
$3.2B
Net Profit
$141.9M
$1.2B
Gross Margin
85.4%
Operating Margin
4.4%
37.8%
Net Margin
3.0%
37.3%
Revenue YoY
0.7%
9.5%
Net Profit YoY
-0.4%
30.5%
EPS (diluted)
$7.35
$4.64

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MUSA
MUSA
VRTX
VRTX
Q4 25
$4.7B
$3.2B
Q3 25
$5.1B
$3.1B
Q2 25
$5.0B
$3.0B
Q1 25
$4.5B
$2.8B
Q4 24
$4.7B
$2.9B
Q3 24
$5.2B
$2.8B
Q2 24
$5.5B
$2.6B
Q1 24
$4.8B
$2.7B
Net Profit
MUSA
MUSA
VRTX
VRTX
Q4 25
$141.9M
$1.2B
Q3 25
$129.9M
$1.1B
Q2 25
$145.6M
$1.0B
Q1 25
$53.2M
$646.3M
Q4 24
$142.5M
$913.0M
Q3 24
$149.2M
$1.0B
Q2 24
$144.8M
$-3.6B
Q1 24
$66.0M
$1.1B
Gross Margin
MUSA
MUSA
VRTX
VRTX
Q4 25
85.4%
Q3 25
86.5%
Q2 25
86.3%
Q1 25
86.9%
Q4 24
85.5%
Q3 24
85.8%
Q2 24
85.9%
Q1 24
87.3%
Operating Margin
MUSA
MUSA
VRTX
VRTX
Q4 25
4.4%
37.8%
Q3 25
3.9%
38.6%
Q2 25
4.4%
38.8%
Q1 25
1.9%
22.7%
Q4 24
4.2%
35.2%
Q3 24
4.2%
40.3%
Q2 24
4.0%
-132.9%
Q1 24
2.2%
42.4%
Net Margin
MUSA
MUSA
VRTX
VRTX
Q4 25
3.0%
37.3%
Q3 25
2.5%
35.2%
Q2 25
2.9%
34.8%
Q1 25
1.2%
23.3%
Q4 24
3.0%
31.4%
Q3 24
2.8%
37.7%
Q2 24
2.7%
-135.8%
Q1 24
1.4%
40.9%
EPS (diluted)
MUSA
MUSA
VRTX
VRTX
Q4 25
$7.35
$4.64
Q3 25
$6.76
$4.20
Q2 25
$7.36
$3.99
Q1 25
$2.63
$2.49
Q4 24
$6.87
$3.62
Q3 24
$7.20
$4.01
Q2 24
$6.92
$-13.92
Q1 24
$3.12
$4.21

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MUSA
MUSA
VRTX
VRTX
Cash + ST InvestmentsLiquidity on hand
$28.9M
$6.6B
Total DebtLower is stronger
$2.2B
Stockholders' EquityBook value
$623.5M
$18.7B
Total Assets
$4.7B
$25.6B
Debt / EquityLower = less leverage
3.47×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MUSA
MUSA
VRTX
VRTX
Q4 25
$28.9M
$6.6B
Q3 25
$42.8M
$6.3B
Q2 25
$54.1M
$6.4B
Q1 25
$49.4M
$6.2B
Q4 24
$47.0M
$6.1B
Q3 24
$52.5M
$6.5B
Q2 24
$79.8M
$5.8B
Q1 24
$56.7M
$10.2B
Total Debt
MUSA
MUSA
VRTX
VRTX
Q4 25
$2.2B
Q3 25
$2.2B
Q2 25
$2.1B
Q1 25
$2.0B
Q4 24
$1.8B
Q3 24
$1.8B
Q2 24
$1.8B
Q1 24
$1.8B
Stockholders' Equity
MUSA
MUSA
VRTX
VRTX
Q4 25
$623.5M
$18.7B
Q3 25
$546.0M
$17.3B
Q2 25
$646.1M
$17.2B
Q1 25
$719.6M
$16.5B
Q4 24
$840.1M
$16.4B
Q3 24
$830.1M
$15.6B
Q2 24
$811.3M
$14.8B
Q1 24
$781.6M
$18.5B
Total Assets
MUSA
MUSA
VRTX
VRTX
Q4 25
$4.7B
$25.6B
Q3 25
$4.7B
$24.9B
Q2 25
$4.6B
$24.0B
Q1 25
$4.5B
$22.9B
Q4 24
$4.5B
$22.5B
Q3 24
$4.4B
$22.2B
Q2 24
$4.4B
$20.1B
Q1 24
$4.3B
$23.9B
Debt / Equity
MUSA
MUSA
VRTX
VRTX
Q4 25
3.47×
Q3 25
4.07×
Q2 25
3.20×
Q1 25
2.74×
Q4 24
2.18×
Q3 24
2.19×
Q2 24
2.20×
Q1 24
2.28×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MUSA
MUSA
VRTX
VRTX
Operating Cash FlowLast quarter
$245.5M
$498.0M
Free Cash FlowOCF − Capex
$128.8M
$348.6M
FCF MarginFCF / Revenue
2.7%
10.9%
Capex IntensityCapex / Revenue
2.5%
4.7%
Cash ConversionOCF / Net Profit
1.73×
0.42×
TTM Free Cash FlowTrailing 4 quarters
$374.3M
$3.2B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MUSA
MUSA
VRTX
VRTX
Q4 25
$245.5M
$498.0M
Q3 25
$184.8M
$1.2B
Q2 25
$255.1M
$1.1B
Q1 25
$128.5M
$818.9M
Q4 24
$248.7M
$584.6M
Q3 24
$202.1M
$1.4B
Q2 24
$260.8M
$-3.8B
Q1 24
$136.0M
$1.3B
Free Cash Flow
MUSA
MUSA
VRTX
VRTX
Q4 25
$128.8M
$348.6M
Q3 25
$67.7M
$1.1B
Q2 25
$137.1M
$927.4M
Q1 25
$40.7M
$778.2M
Q4 24
$121.7M
$492.0M
Q3 24
$65.2M
$1.3B
Q2 24
$142.8M
$-3.8B
Q1 24
$59.8M
$1.2B
FCF Margin
MUSA
MUSA
VRTX
VRTX
Q4 25
2.7%
10.9%
Q3 25
1.3%
37.0%
Q2 25
2.7%
31.3%
Q1 25
0.9%
28.1%
Q4 24
2.6%
16.9%
Q3 24
1.2%
47.0%
Q2 24
2.6%
-144.5%
Q1 24
1.2%
46.0%
Capex Intensity
MUSA
MUSA
VRTX
VRTX
Q4 25
2.5%
4.7%
Q3 25
2.3%
3.3%
Q2 25
2.4%
4.9%
Q1 25
1.9%
1.5%
Q4 24
2.7%
3.2%
Q3 24
2.6%
2.4%
Q2 24
2.2%
2.6%
Q1 24
1.6%
2.5%
Cash Conversion
MUSA
MUSA
VRTX
VRTX
Q4 25
1.73×
0.42×
Q3 25
1.42×
1.15×
Q2 25
1.75×
1.04×
Q1 25
2.42×
1.27×
Q4 24
1.75×
0.64×
Q3 24
1.35×
1.31×
Q2 24
1.80×
Q1 24
2.06×
1.19×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

MUSA
MUSA

Product Sales Petroleum Retail$3.3B69%
Merchandise$1.1B23%
Product Sales Petroleum Wholesale$327.9M7%
Other$57.0M1%
Renewable Identification Numbers$55.3M1%
Revenue Other$1.3M0%

VRTX
VRTX

TRIKAFTAKAFTRIO$2.6B81%
ALYFTREK$380.1M12%
Manufactured Product Other$237.4M7%

Related Comparisons